演題抄録

International Symposium

開催概要
開催回
第52回・2014年・横浜
 

Innvovative Medicine for Gastrointestinal Cancer Stem Cells

演題番号 : TIS2-2

[筆頭演者]
Ishii Hideshi:1 
[共同演者]
Doki Yuuichirou:2、Mori Masaki:2

1:Cancer Profiling Discovery, Graduate School of Medicine, Osaka University、2:Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University

 

Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. However, it is still difficult to cure the patients with advanced cancer radically. This is partly due to the presence of the diversity, or heterogeneity of cancer. The heterogeneity of cancer indicates that cells with different histological differentiation level exist together within the tumors, which contributes to different susceptibility of each cancer cell to anti-cancer reagents or the radiation therapy, and even to life-threatening metastasis. After possible involvement was indicated in leukemia, we reported cancer stem cells (CSCs) firstly in gastrointestinal tumors. Based on the ideitification of CD13/Aminopeptidase N as the candidacy of CSCs of gansrointestinal organs, we have studied how the CSCs survive against the chemotherapy and presumably transform from the dormancy to activated phenotypes, of which studies may link early events of invasion and metastasis and would open an avenue to innovative medicine for the retractable diseases. Here we forcus on the hypoxic cancer metabolism and its possible linkage with epigenome. The present study indicates the rationale that the combination of traditional therapies with targeted CSC-specific agents may target the whole tumors and may offer a promising strategy for lasting treatment and even cure.

前へ戻る